Published on March 6, 2014
Anteo Diagnostics Limited (ASX:ADO) ASX Spotlight Series - New York and London February/March 2014 Presented by Dr. Geoff Cumming Managing Director & CEO “Solid commercial progress and growing revenue streams achieved in 2013 enhance Anteo’s prospects of becoming cash flow positive in CY2014”
Company Snapshot Anteo Diagnostics Limited (“Anteo”) is an Australian biotechnology company that develops, manufactures and commercialises proprietary surface coatings for the global healthcare industry. Corporate Snapshot ADO Cash $7.1M Market Cap. $134 52 week high $0.20 52 week low Major Shareholders ASX $0.05 Shares on issue 814.4M First Cape Mgt Pty Ltd 9.52% Shareholders 4,414 Austcorp 190 Pty Ltd 4.05% Top 20 31% Directors/staff 17% Nimrod Finance Ltd 2.44% Board of Directors Executive Team Mr. Mark Bouris – Non-Executive Chairman Dr. Geoff Cumming – Chief Executive Officer Ms. Sandra (Sam) Andersen – Non-Executive Director Mr. Richard Martin – Executive Director Dr. John Hurrell – Non-Executive Director Dr. Geoff Cumming – Chief Executive Officer Dr. Joe Maeji – Chief Scientific Officer Mr. Richard Martin – Chief Financial Officer Dr. Tina Baumgartner – VP Business Development & Marketing Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 2
Recent Highlights Solid commercial progress and growing revenue streams achieved in 2013… Feb 2013 Sales partnership agreement with U.S. based One World Lab May 2013 Sales partnership agreement with Spanish based Gennova Scientific for Europe & Latin America June 2013 Feasibility agreement with global healthcare company for development of Point of Care device June 2013 Granted European Patent on Mix&Go July 2013 Received a 2-year $1.7M grant with Commercialisation Australia from April 2013 November 2013 Heads of Terms signed with BBI Solutions, a global leader in immunoassay development and manufacturing services …enhancing the company’s prospects of becoming cash flow positive in CY2014 Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 3
Mix&Go - Universal Surface Coating Mix&Go: A Game Changing Product with emerging revenue streams and significant growth potential Mix&Go is a specialized universal “glue”: • uniquely suited for applications in diagnostics and life sciences Mix&Go is applicable to numerous other large healthcare related segments, e.g.: • Separation of proteins and cells • Forms ultrathin (< 1nm) layers that bond strongly • Drug discovery and development • Is gentle and does not damage the activity of fragile biomolecules • Medical devices • Drug delivery • Improves pathology tests earlier disease detection • Reduces cost of test development and manufacture (faster/less Ab required) Mix&Go is well suited to be the “glue” of choice in a variety of applications and industries outside of healthcare, e.g. Resources and Cleantech Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 4
Game Changing Products for Life Sciences Orientation is random 3D structure is damaged Proprietary solution: metal polymers Undamaged, oriented Characteristics Characteristics Benefits Vast majority of proteins are nonfunctional Undamaged, fully functional proteins on surface Increased performance Less non-specific binding Improved protein stability More protein (Ab) needed Less protein and/or beads required Reduced cost Saves valuable, expensive proteins Complicated, time-consuming procedures Easy and fast to use and manufacture Improves efficiency Simpler test procedures Manufacturing faster, easier, more scalable Improved reproducibility Improved accuracy with improved %CV Expert knowledge needed Lower sensitivity, LOD, dynamic range Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 5
Value Creation and Capture Large global healthcare markets underpin revenue growth potential Anteo is targeting large and growing healthcare sectors with Mix&Go. The compelling market opportunities are: • Laboratory Diagnostics: Encompassing the global IVD market valued at $44 billion in 2011, including the immunoassay sector at $8.8 billion • Point-of-Care: Expected size of market by 2017 is $38 billion • Rapid Test Products: Valued at $3.7 billion in 2012 • Life Science R&D: A very large and diverse $1 billion sector • Bioseparations: Encompassing protein and protein drug manufacturing sector valued at up to $5 billion Anteo has multiple and recurring revenue streams including: • Development Fees: From $250,000+ per full-time employee • License Fees: From $150,000 + p.a • Ongoing Royalties: On sales from products containing Mix&Go Potential royalty earnings vary depending on the size of the company and the degree of benefit Mix&Go can bring. Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 6
Milestones 2014 2014 2015 Advancing near-term value accretive opportunities that will translate quickly into revenue…. License and supply agreement with global point-of-care company Extension of agreement with global lateral flow company Anteo Mix&Go (AMG) bead and plate products launched in Australia Pipeline of additional, unique, value-added solutions for the R&D space realised with partners worldwide Anteo is commencing its next phase of product development Anteo filed two sets of patent applications in August 2013. These patents will complement the existing Mix&Go patent portfolio, and expand the protected areas of application to bioseparations, drug screening, drug delivery and areas outside the health care industry, e.g., in clean tech and resources sectors. Anteo has 4 advanced projects and ongoing pipeline development. We expect to close deals with 10 or more medium to large companies during next 4 years. Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 7
Bioseparation – Anteo’s Next Opportunity Current Approach Paradigm Shift Chromatography: • Time consuming • Expensive • Hard to automate • Capacity constraints With Mix&Go magnetic separation can become reality • Technically superior solution • Economically advantageous Alternative Large Opportunities Magnetic separation: • Technically superior • Currently unaffordable • • • Protein and protein drug manufacturing: $35B Vaccine manufacturing: $620M in 2015 Stem cell therapy market,: $1 B, CAGR 30% Leverage Mix&Go in bioseparations to create significant long-term revenue streams for Anteo Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 8
Anteo’s Opportunities Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 9
Anteo’s Keypoints Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond Mix&Go is proven licensed and gaining significant traction in commercial markets Mix&Go success means Anteo is becoming cash flow positive Strong near term value drivers Focus on diagnostics and life sciences with expansion into bioseparations provides Anteo significant revenue opportunities Strong leadership - Board and management team in place to drive growth Global team, resources and network to capitalise on growth opportunity Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 10
Contact Information Thank you very much for your interest in Anteo Diagnostics For more information please contact: Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 11
Forward Looking Statement The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 12
Gage-Cannon helps ventures accelerate organic growth or obtain equity funding, and...
Foro MAB Sevilla 13 de noviembre de 2014
Analyst presentation third quarter 2014 results. ING posts 3Q14 underlying net pro...
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 5 Undamaged, oriented Characteristics Benefits Undamaged, fully functional ...
Anteo Diagnostics ASX Spotlight Presentation March 2014 from Matt Sanderson
PRESENTATIONS; FINANCIAL REPORTS; ... Anteo Diagnostics (ASX: ADO) ... email@example.com. Unit 4, 26 Brandl Street, ...
Anteo Diagnostics: ASX Spotlight Presentation 2014 February 27, 2014 03:40 PM. Anteo Diagnostics Limited (ASX: ...
Vision Research Anteo Diagnostics Charts
ANTEO DIAGNOSTICS LIMITED company information for investors. ... ASX Spotlight Series; ... Investor Presentation : Wed, 20 May ...
Anteo Diagnostics (ASX:ADO) ... This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited.